A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
Patients able to give written informed consent;
Age ≥ 18 and ≤ 75 years old, male or female;
Patients have histological or cytological diagnosis with advanced solid tumors ( especially SCLC or LCNEC);
Willingness to provide tumor tissue for testing ;
Patients who have had previous treatment with any anti-DLL3 antibody；
Have had other malignant tumors in the past 5 years;
Patients who are receiving other anti-tumor treatments within 4 weeks prior to the first dose;
Have active CNS (central nervous system) metastasis；